New pharmaceutical interventions, including glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide/Ozempic TM and Wegovy TM ) and dual gastric inhibitory polypeptide and GLP-1 (GIP/GLP-1) receptor agonists (e.g., tirzepatide), demonstrate significant weight-loss efficacy
Irregular dosing produces irregular results
In our experience, these results can be considered above average, which may be attributed to the users diligent dieting to lose the last 40 pounds, where they reported eliminating sugar and cheese from their diet
This emotional toll compounds the already challenging nature of obesity treatment
Consult a licensed physician for any medical decisions.
Author contributions The authors confirm their contribution to the paper as follows: Yusoff Umul Hanimperformed, analyzed, and designed the structure of the manuscript